Novartis Halts Heart Trial, Touts Positive Phase III Results

Drug Industry Daily
Novartis said Monday it has halted the Phase III trial of its chronic heart failure drug LCZ696 after being notified by a data monitoring committee that the drug met its composite primary endpoint of delayed cardiovascular death and reduced heart failure hospitalizations.

To View This Article:


Subscribe To Drug Industry Daily